MA46255A - Vaccins anticancéreux - Google Patents
Vaccins anticancéreuxInfo
- Publication number
- MA46255A MA46255A MA046255A MA46255A MA46255A MA 46255 A MA46255 A MA 46255A MA 046255 A MA046255 A MA 046255A MA 46255 A MA46255 A MA 46255A MA 46255 A MA46255 A MA 46255A
- Authority
- MA
- Morocco
- Prior art keywords
- cancer vaccines
- vaccines
- cancer
- Prior art date
Links
- 229940022399 cancer vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245031P | 2015-10-22 | 2015-10-22 | |
| US201562245129P | 2015-10-22 | 2015-10-22 | |
| US201562247317P | 2015-10-28 | 2015-10-28 | |
| US201562247472P | 2015-10-28 | 2015-10-28 | |
| US201662368810P | 2016-07-29 | 2016-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46255A true MA46255A (fr) | 2019-07-31 |
Family
ID=58558197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046255A MA46255A (fr) | 2015-10-22 | 2016-10-21 | Vaccins anticancéreux |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180318409A1 (fr) |
| EP (1) | EP3364949A4 (fr) |
| JP (2) | JP2018532777A (fr) |
| CN (2) | CN108430456B (fr) |
| AU (2) | AU2016341309A1 (fr) |
| CA (1) | CA3003090A1 (fr) |
| MA (1) | MA46255A (fr) |
| WO (1) | WO2017070618A1 (fr) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| LT4023249T (lt) | 2014-04-23 | 2025-01-10 | Modernatx, Inc. | Nuleorūgšties vakcinos |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| EP4218805A1 (fr) | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Vaccins contre les maladies infectieuses |
| WO2017020026A1 (fr) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Arn épitopes peptidiques concatémériques |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| MA47016A (fr) | 2015-10-22 | 2018-08-29 | Modernatx Inc | Vaccins contre les virus respiratoires |
| WO2017070616A2 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccins contre les maladies sexuellement transmissibles |
| CN108472309A (zh) | 2015-10-22 | 2018-08-31 | 摩登纳特斯有限公司 | 用于水痘带状疱疹病毒（vzv）的核酸疫苗 |
| AU2016342045A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP3364950A4 (fr) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Vaccins contre des maladies tropicales |
| SI3386484T1 (sl) | 2015-12-10 | 2022-06-30 | Modernatx, Inc. | Sestave in metode za dovajanje terapevtskih sredstev |
| US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
| MA45052A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille |
| IL263079B2 (en) | 2016-05-18 | 2024-05-01 | Modernatx Inc | Polynucleotides encoding relaxin |
| SG11201901941YA (en) | 2016-09-14 | 2019-04-29 | Modernatx Inc | High purity rna compositions and methods for preparation thereof |
| CA3041307A1 (fr) | 2016-10-21 | 2018-04-26 | Giuseppe Ciaramella | Vaccin contre le cytomegalovirus humain |
| EP3538146A4 (fr) | 2016-11-11 | 2020-07-15 | ModernaTX, Inc. | Vaccin antigrippal |
| EP3551193A4 (fr) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | Vaccins à acide nucléique contre des virus respiratoires |
| EP3555289A1 (fr) | 2016-12-13 | 2019-10-23 | ModernaTX, Inc. | Purification par affinité d'arn |
| CA3049926A1 (fr) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Inhibiteurs de proteine kinase pour favoriser la regeneration du foie, ou pour reduire ou prevenir la mort des hepatocytes |
| KR20190110612A (ko) * | 2017-02-01 | 2019-09-30 | 모더나티엑스, 인크. | 활성화 종양유전자 돌연변이 펩티드를 인코드하는 면역조절 치료 mrna 조성물 |
| SG11201906895WA (en) * | 2017-02-01 | 2019-08-27 | Modernatx Inc | Rna cancer vaccines |
| EP3579885A4 (fr) * | 2017-02-07 | 2020-12-16 | Nantcell, Inc. | Maximisation de la mémoire de cellules t, compositions et méthodes associées |
| MA47515A (fr) | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
| WO2018170245A1 (fr) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Vaccin à large spectre contre le virus de la grippe |
| MA47787A (fr) | 2017-03-15 | 2020-01-22 | Modernatx Inc | Vaccin contre le virus respiratoire syncytial |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
| WO2018170347A1 (fr) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Vaccins à base d'arn contre des maladies zoonotiques |
| WO2018187590A1 (fr) | 2017-04-05 | 2018-10-11 | Modernatx, Inc. | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| US11554178B2 (en) * | 2017-06-30 | 2023-01-17 | City Of Hope | Compositions and methods of modulating macrophage activity |
| EP3668979A4 (fr) | 2017-08-18 | 2021-06-02 | Modernatx, Inc. | Procédés pour analyse par clhp |
| EP3668971B8 (fr) | 2017-08-18 | 2024-05-29 | ModernaTX, Inc. | Variants d'arn polymérase |
| WO2019036683A1 (fr) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | Procédés analytiques par hplc |
| JP7275111B2 (ja) | 2017-08-31 | 2023-05-17 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子の生成方法 |
| EP3681514A4 (fr) | 2017-09-14 | 2021-07-14 | ModernaTX, Inc. | Vaccins à arn contre le virus zika |
| GB2574785A (en) | 2017-09-15 | 2019-12-25 | Jan Loetvall | Method and system for identifying membrane proteins on extracellular vesicles |
| CN118512583A (zh) * | 2017-12-27 | 2024-08-20 | 武田药品工业株式会社 | 含核酸脂质纳米粒子及其用途 |
| MA54676A (fr) | 2018-01-29 | 2021-11-17 | Modernatx Inc | Vaccins à base d'arn contre le vrs |
| AU2019219200B2 (en) * | 2018-02-12 | 2025-02-13 | BioNTech SE | Treatment using cytokine encoding RNA |
| SG11202012770RA (en) * | 2018-06-27 | 2021-01-28 | Modernatx Inc | Personalized cancer vaccine epitope selection |
| WO2020020444A1 (fr) * | 2018-07-24 | 2020-01-30 | Biontech Rna Pharmaceuticals Gmbh | Vaccins individualisés pour le cancer |
| WO2020061284A1 (fr) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Lipides peg et leurs utilisations |
| CN113271926A (zh) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
| CA3114699A1 (fr) | 2018-10-09 | 2020-04-16 | The University Of British Columbia | Compositions et systemes comprenant des vesicules competentes pour la transfection exemptes de solvants organiques et de detergents, et procedes associes |
| US20210381060A1 (en) * | 2018-10-29 | 2021-12-09 | Health Research, Inc. | Cancer specific immunotherapeutic targets generated by chemotherapeutic drug treatment |
| US20210388023A1 (en) * | 2018-11-06 | 2021-12-16 | Merck Sharp & Dohme Corp. | Analytical tool for characterization of lipid nanoparticles |
| AU2019374818A1 (en) * | 2018-11-07 | 2021-05-27 | Modernatx, Inc. | RNA cancer vaccines |
| SG11202103243PA (en) * | 2018-11-15 | 2021-04-29 | Nouscom Ag | Selection of cancer mutations for generation of a personalized cancer vaccine |
| EP3908262A4 (fr) * | 2019-01-09 | 2022-12-28 | Exocure Biosciences, Inc. | Vésicules dérivées de bactéries et leurs utilisations |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CN113365653A (zh) * | 2019-01-18 | 2021-09-07 | 佐治亚大学研究基金会股份有限公司 | 盐纳米颗粒和组合物及其使用方法 |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| MX2021010075A (es) | 2019-02-20 | 2021-12-10 | Modernatx Inc | Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales. |
| EP3938379A4 (fr) | 2019-03-15 | 2023-02-22 | ModernaTX, Inc. | Vaccins à base d'arn contre le vih |
| EP4004021A4 (fr) * | 2019-07-22 | 2023-09-27 | Oneskin, Inc. | Polypeptides ayant des effets anti-sénescence et leurs utilisations |
| CN114502204A (zh) * | 2019-08-14 | 2022-05-13 | 库尔维科公司 | 具有降低的免疫刺激性质的rna组合和组合物 |
| WO2021099906A1 (fr) | 2019-11-18 | 2021-05-27 | Janssen Biotech, Inc. | Vaccins basés sur les mutants du gène calr et de la protéine jak2 et leurs utilisations |
| US20230022045A1 (en) * | 2019-12-03 | 2023-01-26 | Board Of Regents, The University Of Texas System | Combination therapies for the treatment of cancer |
| AU2021222036A1 (en) * | 2020-02-19 | 2022-09-22 | University Of Florida Research Foundation, Incorporated | Multilamellar RNA nanoparticles and methods of sensitizing tumors to treatment with immune checkpoint inhibitors |
| WO2021213924A1 (fr) | 2020-04-22 | 2021-10-28 | BioNTech SE | Vaccin contre un coronavirus |
| KR20230034333A (ko) | 2020-07-02 | 2023-03-09 | 라이프 테크놀로지스 코포레이션 | 트리뉴클레오티드 캡 유사체, 제조 및 이의 용도 |
| CN111773381A (zh) * | 2020-07-06 | 2020-10-16 | 贵阳市第二人民医院 | 一种靶向tem-1基因疫苗及其构建与应用 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| WO2022120560A1 (fr) * | 2020-12-08 | 2022-06-16 | 深圳市瑞吉生物科技有限公司 | Immunosuppresseur sous forme posologique d'arnm et son application dans la préparation d'un médicament pour le traitement de tumeurs |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| MX2024001243A (es) * | 2021-07-29 | 2024-02-13 | BioNTech SE | Composiciones y metodos para el tratamiento de melanoma. |
| WO2023031394A1 (fr) | 2021-09-03 | 2023-03-09 | CureVac SE | Nouvelles nanoparticules lipidiques pour l'administration d'acides nucléiques |
| CA3232725A1 (fr) * | 2021-09-22 | 2023-03-30 | Steven Gregory REED | Compositions de therapie anticancereuse et leurs utilisations |
| WO2023069625A1 (fr) * | 2021-10-20 | 2023-04-27 | Modernatx, Inc. | Solutions de substitution de produit médicamenteux |
| EP4422698A1 (fr) | 2021-10-29 | 2024-09-04 | CureVac SE | Arn circulaire amélioré pour exprimer des protéines thérapeutiques |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| WO2023144330A1 (fr) | 2022-01-28 | 2023-08-03 | CureVac SE | Inhibiteurs de facteurs de transcription codés par un acide nucleique |
| TW202405168A (zh) * | 2022-04-08 | 2024-02-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 製造含有寡核苷酸之聚核苷酸的新穎方法 |
| WO2023227608A1 (fr) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Vaccin à base d'acide nucléique codant pour un polypeptide antigénique fimh d'escherichia coli |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| WO2024004159A1 (fr) * | 2022-06-30 | 2024-01-04 | Ｅｐｓ創薬株式会社 | Composition de vaccin pour une administration sublinguale |
| US12186389B2 (en) | 2022-10-28 | 2025-01-07 | Glaxosmithkline Biologicals Sa | Nucleic acid base vaccine against emerging SARS-CoV-2 variants |
| CN116083463B (zh) * | 2022-12-16 | 2024-06-21 | 四川大学华西医院 | 一种用于增强免疫疗法效果的mRNA及其在制备mRNA疫苗中的用途 |
| CN115671045B (zh) * | 2022-12-30 | 2023-04-07 | 华南理工大学 | 非肝靶向的核酸纳米制剂及其制备方法和应用 |
| WO2024153000A1 (fr) * | 2023-01-17 | 2024-07-25 | The University Of Hong Kong | Immunothérapie anticancéreuse par administration d'arnm |
| WO2024184500A1 (fr) | 2023-03-08 | 2024-09-12 | CureVac SE | Nouvelles formulations de nanoparticules lipidiques pour l'administration d'acides nucléiques |
| WO2024230934A1 (fr) | 2023-05-11 | 2024-11-14 | CureVac SE | Acide nucléique thérapeutique pour le traitement de maladies ophtalmiques |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6432925B1 (en) * | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
| CN1129667C (zh) * | 2001-12-26 | 2003-12-03 | 中国人民解放军第二军医大学 | 治疗肿瘤的自体免疫细胞及其制备方法 |
| US20040175813A1 (en) * | 2002-05-24 | 2004-09-09 | Kimberly Kline | Mutant P53 proteins and uses thereof |
| HUE049886T2 (hu) * | 2010-05-14 | 2020-10-28 | Massachusetts Gen Hospital | Tumorspecifikus neoantigéneket tartalmazó készítmények, tumorok kezelésében történõ alkalmazásra |
| SMT202300161T1 (it) * | 2011-05-24 | 2023-07-20 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Vaccini individualizzati per il cancro |
| JP6120839B2 (ja) * | 2011-07-06 | 2017-04-26 | ノバルティス アーゲー | カチオン性水中油型エマルジョン |
| WO2013086373A1 (fr) * | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipides pour l'administration d'agents actifs |
| WO2013090648A1 (fr) * | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Nucléoside, nucléotide, et compositions d'acide nucléique modifiés |
| WO2013143555A1 (fr) * | 2012-03-26 | 2013-10-03 | Biontech Ag | Formulation d'arn pour immunothérapie |
| JP2015513913A (ja) * | 2012-04-02 | 2015-05-18 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 修飾ポリヌクレオチド |
| AU2013243949A1 (en) * | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| US10155031B2 (en) * | 2012-11-28 | 2018-12-18 | Biontech Rna Pharmaceuticals Gmbh | Individualized vaccines for cancer |
| US10130649B2 (en) * | 2013-03-15 | 2018-11-20 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| EP3041934A1 (fr) * | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Polynucléotides chimériques |
| JP6525435B2 (ja) * | 2013-10-22 | 2019-06-12 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | メッセンジャーｒｎａの送達のための脂質製剤 |
| EP3556353A3 (fr) * | 2014-02-25 | 2020-03-18 | Merck Sharp & Dohme Corp. | Adjuvants de vaccins à nanoparticules lipidiques et systèmes d'administration d'antigènes |
| RS63848B1 (sr) * | 2014-06-25 | 2023-01-31 | Acuitas Therapeutics Inc | Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina |
| WO2017020026A1 (fr) * | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Arn épitopes peptidiques concatémériques |
-
2016
- 2016-10-21 MA MA046255A patent/MA46255A/fr unknown
- 2016-10-21 AU AU2016341309A patent/AU2016341309A1/en not_active Abandoned
- 2016-10-21 CN CN201680075024.0A patent/CN108430456B/zh active Active
- 2016-10-21 US US15/769,710 patent/US20180318409A1/en active Pending
- 2016-10-21 EP EP16858398.7A patent/EP3364949A4/fr active Pending
- 2016-10-21 WO PCT/US2016/058317 patent/WO2017070618A1/fr active Application Filing
- 2016-10-21 CN CN202111635839.9A patent/CN114404581A/zh active Pending
- 2016-10-21 CA CA3003090A patent/CA3003090A1/fr active Pending
- 2016-10-21 JP JP2018541087A patent/JP2018532777A/ja active Pending
-
2022
- 2022-12-22 JP JP2022205615A patent/JP7625568B2/ja active Active
-
2024
- 2024-01-23 AU AU2024200425A patent/AU2024200425B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114404581A (zh) | 2022-04-29 |
| JP7625568B2 (ja) | 2025-02-03 |
| AU2024200425A1 (en) | 2024-02-15 |
| AU2024200425B2 (en) | 2025-02-27 |
| EP3364949A4 (fr) | 2019-07-31 |
| WO2017070618A1 (fr) | 2017-04-27 |
| US20180318409A1 (en) | 2018-11-08 |
| EP3364949A1 (fr) | 2018-08-29 |
| CA3003090A1 (fr) | 2017-04-27 |
| JP2018532777A (ja) | 2018-11-08 |
| JP2023024669A (ja) | 2023-02-16 |
| AU2016341309A1 (en) | 2018-06-07 |
| CN108430456B (zh) | 2022-01-18 |
| CN108430456A (zh) | 2018-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46255A (fr) | Vaccins anticancéreux | |
| DK3393510T5 (da) | Zikavirusvaccine | |
| MA52645A (fr) | Vaccins contre le virus respiratoire | |
| MA46378A (fr) | Vaccins hpv16 thérapeutiques | |
| GB201410971D0 (en) | Vaccine | |
| GB201518684D0 (en) | Vaccine | |
| SMT202400518T1 (it) | Composizioni anticancro | |
| LT3226842T (lt) | Priešvėžinės kompozicijos | |
| LT3226843T (lt) | Priešvėžinės kompozicijos | |
| EP3220961C0 (fr) | Conjugués de vitamine d thérapeutiques | |
| DK3171700T3 (da) | Infusionsanlæg | |
| DK3199161T3 (da) | Farmaceutisk præparat | |
| EP3237013C0 (fr) | Formulations transdermiques | |
| DK3129007T3 (da) | Vaccinesammensætninger | |
| HK1257910A1 (zh) | 卵巢癌疫苗 | |
| EP3560512A4 (fr) | Composition de vaccin contre le zona | |
| GB201522132D0 (en) | Vaccine | |
| DK3205661T3 (da) | Hsp70-afledt immunitetsinducerende peptid | |
| EP3528843A4 (fr) | Vaccins anti-opioïdes | |
| GB201616904D0 (en) | Vaccine | |
| DK3405212T3 (da) | Cancervacciner | |
| EP3395344A4 (fr) | Médicament | |
| PL3322718T3 (pl) | Histonowe szczepionki przeciwnowotworowe | |
| HUE050881T2 (hu) | Gyógyszerkészítmény | |
| LT3188755T (lt) | Vakcina |